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Human papillomaviruses, mainly type 16 (HPV16), are responsible for cervical intraepithelial neoplasia, which can lead, in
association with other factors, to cervical cancer. Both Salmonella recombinant vaccine strains assembling HPV16 virus-like
particles (VLPs) and HPV16 VLPs purified from insect cells are able to induce HPV16 neutralizing antibodies in genital
secretions of mice after nasal immunization. Anti-HPV16-specific antibodies in cervical secretions of women may prevent
genital infection with HPV16, although this cannot be critically evaluated in the absence of an experimental model for genital
papillomavirus infection. Induction of HPV16-specific cell-mediated immunity in the genital mucosa could improve the
efficacy of a vaccine and a mucosal route of immunization might be necessary to do so. It has been shown that systemic
immunization of mice with purified HPV16 VLPs confers protection against an HPV16-expressing tumor cell challenge
through the induction of cytotoxic T-lymphocytes. Using the same C3 tumor model, we show that intranasal immunization of
mice with purified HPV16 VLPs in a prophylactic setting also induces anti-tumor immunity. More interestingly, mucosal
vaccination of mice with a Salmonella recombinant strain stably expressing HPV16 L1 VLPs also induces anti-tumor immunity
in prophylactic as well as in therapeutic settings. Our data suggest that attenuated Salmonella strains expressing chimeric
VLPs containing nonstructural viral proteins might be a promising candidate vaccine against cervical cancer by inducing both
neutralizing antibodies and cell-mediated immunity. © 2001 Academic Press
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The “high-risk” human papillomavirus types, most
commonly type 16 (HPV16), are etiologically linked to
close to 100% of cervical cancers (Walboomers et al.,
1999). Cervical cancer is the second leading cause of
cancer deaths in women worldwide, encouraging the
development of a prophylactic vaccine to prevent genital
infection by these viruses. Papillomavirus virus-like par-
ticles (VLPs) self-assemble after high-level expression of
the papillomavirus L1 virion capsid protein in nonmam-
malian cells (Kirnbauer et al., 1992, 1993; Hagensee et
l., 1993; Rose et al., 1994; Sasagawa et al., 1995; Hof-
mann et al., 1995; Nardelli-Haefliger et al., 1997). Several
accine trials using purified VLPs are currently ongoing
ased on the following encouraging results obtained in
nimal studies: (1) immunization with VLPs generates
ype-specific neutralizing antibodies and protection from
xperimental challenge (Rose et al., 1994; Sasagawa et
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354l., 1995; Suzich et al., 1995; Breitburd et al., 1995; Kirn-
auer et al., 1996) and (2) passive transfer of IgG indi-
ates that protection does not require cell-mediated ef-
ector immune responses. However, protection from cer-
ical infection cannot be critically evaluated in the
bsence of an animal model in which to examine pro-
ection from natural venereal transmission of a mucosa-
ropic papillomavirus. In an effort to generate improved
PV vaccines with additional therapeutic potentials, chi-
eric VLPs containing the E7 oncoprotein were recently
ngineered and shown to induce cytotoxic T-lymphocyte
CTL)-mediated rejection of syngeneic HPV16 E7-ex-
ressing tumor cells implanted into the flank of mice
ollowing parenteral administration (Muller et al., 1997;
reenstone et al., 1998; Schafer et al., 1999). HPV16
1-only VLPs can also protect against experimental tu-
or challenge, providing the tumor cells express HPV16
1 (De Bruijn et al., 1998). However, it has been reported
hat a mucosal route of immunization is necessary in
rder to provide long-term immunity and CTL-mediated
rotection against herpes simplex virus type 2 in the
urine genital tract (Gallichan and Rosenthal, 1996,
998). We have already shown that mucosal immuniza-
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355RECOMBINANT Salmonella/HPV16 L1 VACCINATION INDUCES ANTI-TUMOR ACTIVITYtion with purified VLPs is necessary to induce HPV-
neutralizing titers throughout the menstrual cycle of mice
(Nardelli-Haefliger et al., 1999). Whether this might also
be true for inducing CTL-mediated long-term protection
against genital papillomavirus is not known. As a first
step to address this question, we vaccinated mice intra-
nasally with purified VLPs or live attenuated HPV16 L1
recombinant Salmonella typhimurium strains and ana-
yzed their ability to inhibit the outgrowth of HPV16-
xpressing tumor cells (Feltkamp et al., 1993). Salmo-
ella vaccine strains are effective vehicles for delivering
eterologous antigens to the mucosal and systemic im-
une systems (Curtiss, 1990) where, in addition to hu-
oral immunity, they can induce specific CTLs and pro-
ide anti-tumor immunity (Roberts et al., 1994; Sztein et
l., 1995; Valentine et al., 1996; Medina et al., 1999). We
reviously reported that immunization with a PhoPc S.
typhimurium strain expressing HPV16 L1 induced HPV16
neutralizing antibodies in mice (Nardelli-Haefliger et al.,
1997). Here we show that mucosal immunization with a
similar strain stably expressing HPV16 L1 also provides
growth inhibition of HPV16-expressing tumor cells in
both prophylactic and therapeutic settings. Furthermore,
intranasal vaccination with purified HPV16 VLPs also
inhibited tumor growth, at least in the prophylactic set-
ting.
RESULTS AND DISCUSSION
Nasal vaccination with purified HPV16 VLPs inhibits
the growth of the HPV16-expressing C3 tumor cells (Felt-
kamp et al., 1993). Four groups of 8 to 10 mice were used.
FIG. 1. Both i.n. and sc immunization of mice with purified HPV16
immunization group at the indicated time-points. Error bars indicate sta
for each immunization group at day 35 after C3 cell challenge. Tumor-fre
volumes of each group are shown by horizontal bars. Statistical compOne group was subcutaneously (sc) immunized twice
with 5 mg HPV16 VLPs at 2-week intervals and the three
2
Iother groups were intranasally (i.n.) immunized three
times at weekly intervals with PBS or with 5 mg HPV16
VLPs, either with or without 5 mg of the mucosal adjuvant
cholera toxin (CT). Two weeks after the last immunization
all the mice were challenged with C3 cells. After 10 days,
tumor growth was measured in each mouse twice a
week and the mean volumes are reported in Fig. 1A.
Variable tumor take or growth rate was observed be-
tween individual mice as well as between experiments.
This is illustrated in Fig. 1B, where tumor volumes of
individual mice are shown at day 35 after C3 cell chal-
lenge. Intranasal administration of VLPs in the absence
of CT greatly inhibited tumor growth compared to the
control mice (P , 0.01). This tumor protection effect
was not statistically different whether the VLPs were
administered i.n. in the presence of CT or sc. Further-
more, the level of tumor protection achieved by two sc
injections with 5 mg VLPs (8 of 10 tumor-free mice; see
Fig. 1B) was similar to that reported by De Bruijn et al.
(1998) for two sc injections with 20 mg. Our data demon-
strate that three nasal doses of purified VLPs are as
efficient as parenteral administration of two VLP doses
for preventing the outgrowth of C3 cells sc injected into
mice after immunization.
The PhoPcDasd (GL01) attenuated S. typhimurium
strain stably expressing HPV16 L1 inhibits the growth of
C3 tumor cells. We next examined inhibition of tumor
growth after two i.n. immunizations at 2-week intervals
with the S. typhimurium recombinant strain PhoPc/
PV16L1. Unfortunately, we did not observe a tumor
rotection effect when C3 cell challenge was performed
inhibit C3 cell growth. (A) Mean tumor volumes are shown for each
rrors of the mean. (B) The tumor volumes of individual mice are shown
are indicated by the respective symbols under the x axis. Mean tumor
of the means were carried out using Student’s t test.VLPs
ndard eweeks after the last immunization (data not shown).
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356 REVAZ ET AL.Salmonella strains was reported at later time points
(between 4 and 10 weeks (Aggarwal et al., 1990; Flynn et
l., 1990)). A slight inhibition of tumor growth was indeed
bserved when C3 cell challenge was performed 4
eeks after the last immunization; however, this was not
tatistically significant (data not shown). Because the
lasmid encoding HPV16 L1 is not stable in vivo in the
hoPc strain (Nardelli-Haefliger et al., 1997), we tested
whether tumor growth could be impaired when immuni-
zation was performed with a strain that stably expresses
HPV16 L1, i.e., the GL01/HPV16L1 strain. Three groups of
10 mice were immunized i.n. twice at 2-week intervals
with PBS, 107 CFU of GL01/pYA3342, or 107 CFU of
GL01/HPV16L1. Four weeks after the last immunization
all the mice were sc challenged with C3 cells. After 10
days, tumor growth was measured in each mouse twice
a week and the mean volumes are reported in Fig. 2.
Tumor growth was greatly inhibited in the mice immu-
nized with the recombinant S. typhimurium strain ex-
pressing HPV16 L1 (P , 0.01) and 8 of 10 mice re-
ained tumor free. No effect was noted in the mice
mmunized with the S. typhimurium strain carrying the
ame plasmid but without L1. Inhibition of tumor growth
y GL01/HPV16L1 was observed in two additional inde-
endent experiments, although different numbers of tu-
or-free mice were achieved (4/10 and 6/8, data not
hown). Our data indicate that the tumor growth inhibi-
ion was induced by the stable expression of HPV16 L1
n the GL01 Salmonella strain.
Both oral immunization and nasal immunization with
L01/HPV16L1 inhibit the growth of C3 tumor cells. Be-
FIG. 2. Intranasal immunization of mice with GL01/HPV16L1 inhibits
roup at the indicated time-points. Error bars indicate standard errors
mmunization group at day 46 after C3 cell challenge. Tumor-free mice a
of each group are shown by horizontal bars. Statistical comparisons oause this is the first reported HPV16 tumor growth
nhibition induced by a recombinant Salmonella strain,e have further compared different protocols of immu-
ization. For this purpose, five groups of five mice were
ompared (see Fig. 3A). Two groups were i.n. (107 CFU,
group B in Fig. 3) or orally (109 CFU, group C) immunized
twice at 2-week intervals with GL01/HPV16L1, one group
was immunized only once i.n. with 107 CFU of GL01/
HPV16L1 (group E), and one group was immunized twice
i.n. with PBS as control (group A). All these mice were sc
challenged with C3 cells 4 weeks after the last immuni-
zation (week 6), while a final group of mice received a
2-week-spaced double nasal immunization with 107 CFU
f GL01/HPV16L1 2 weeks before C3 challenge (group
). Examination of tumor growth at day 33 (see Fig. 3B)
evealed that both oral and i.n. immunization inhibited
umor growth compared to the control (P , 0.001 and
, 0.01, respectively) and that a single i.n. immuniza-
tion was sufficient to do so (P , 0.05). The differences
n tumor protection between the treatments tested were
ot statistically significant. Interestingly, a tumor protec-
ion effect was also achieved when the C3 cell challenge
as performed only 2 weeks after the last immunization
P , 0.001). This suggests that the protective immune
esponse induced by the Salmonella recombinant strain
s already effective 2 weeks after immunization.
Immunization with purified HPV16 VLPs or GL01/
PV16L1 can inhibit the growth of previously implanted
3 tumor cells. In order to establish whether inhibition of
PV16 tumor growth could occur in a therapeutic setting,
ive groups of 6 to 10 mice were immunized twice at
-week intervals 6 days after sc injection of C3 cells. Two
roups of mice were i.n. or sc immunized with 5 mg VLPs
7
ll growth. (A) Mean tumor volumes are shown for each immunization
mean. (B) The tumor volumes of individual mice are shown for each
ated by the respective symbols under the x axis. Mean tumor volumes
eans were carried out using Student’s t test.C3 ce
of theand three groups of mice were i.n. immunized with 10
CFU GL01/HPV16L1, 107 CFU GL01/pYA3342, or PBS.
mbols
t using
357RECOMBINANT Salmonella/HPV16 L1 VACCINATION INDUCES ANTI-TUMOR ACTIVITYExamination of tumor growth at day 32 (Fig. 4) revealed
that the growth of the tumors was strongly inhibited by sc
immunization with purified VLPs (P , 0.001) and i.n.
immunization with the recombinant Salmonella GL01 ex-
pressing HPV16 L1 (P , 0.001) compared to the control
mice. Surprisingly, although 2 of 10 mice exhibited a
complete tumor regression, i.n. immunization did not
induce a statistically significant effect. This might be due
to the single mouse that developed a huge tumor (see
Fig. 4), reflecting a variable effect of i.n. immunization
with three VLPs doses in the therapeutic setting. A sig-
nificant inhibition of tumor growth was also observed
when immunization was performed with GL01 not ex-
pressing the HPV16 L1 antigen (P , 0.01). This indi-
cates that Salmonella has an inherent anti-tumor activity
FIG. 3. Comparison between different protocols of immunization usin
indicated (A, B, C, D, and E; see also text). w, week (B) The tumor volum
C3 cell challenge. Tumor-free mice are indicated by the respective sy
horizontal bars. Statistical comparisons of the means were carried ou(Pawelek et al., 1997), possibly mediated by the innate
immunity induced at the time of bacterial infection (6days after C3 cell challenge) or direct toxic effects in-
duced by the Salmonella. In contrast, in the prophylactic
setting bacteria were mostly cleared at the time of C3
cell challenge (4 weeks after the last immunization
(Benyacoub et al., 1999)). Nevertheless, immunization
with GL01/HPV16L1 provided a significantly higher tumor
protection (P , 0.01 compared to GL01/pYA3342) indi-
cating that L1-specific anti-tumor immunity is clearly ben-
eficial.
Our study demonstrates that nasal immunization with
purified HPV16 VLPs inhibits the growth of HPV16-ex-
pressing tumor cells implanted sc at least in the prophy-
lactic setting. These data, together with the reported
capacity of this type of vaccination to induce specific
CTLs in the vaginal draining lymph nodes (Dupuy et al.,
/HPV16L1. (A) Experimental protocol. The five immunization groups are
ndividual mice are shown for each immunization group at day 33 after
under the x axis. Mean tumor volumes of each group are shown by
Student’s t test.g GL01
es of i1999), suggest that the nasal route of immunization might
be able to inhibit outgrowth of HPV-infected cells located
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358 REVAZ ET AL.in the genital mucosa. We also report for the first time
that a recombinant Salmonella strain stably expressing
PV16 L1 is able to prevent outgrowth of HPV16-ex-
ressing tumor cells in both a prophylactic and a thera-
eutic setting. This probably occurs through the induc-
ion of HPV16-specific CTLs as shown after vaccination
ith VLPs or cVLPs (De Bruijn et al., 1998; Schafer et al.,
999), although some bystander anti-tumor effect of Sal-
onella could also play a role as observed in the ther-
peutic setting. Unfortunately, all our attempts to mea-
ure L1-specific CTLs in vitro have failed due to the lack
f efficient MHC I L1-presenting cells and because, in
ontrast to E7, the CTL epitopes of L1 have not been
apped. Interestingly, in contrast to the induction of
nti-HPV16VLP antibodies (Nardelli-Haefliger et al.,
997), oral immunization and nasal immunization were
ffective at inducing anti-tumor immunity. However, sta-
le expression of HPV16 L1 was required. HPV16 E7
pitopes or proteins have been previously expressed in
almonella; however, they failed to induce E7-specific
TL responses (Street et al., 1999), or no E7-specific
ell-mediated immunity (CMI) was reported (Krul et al.,
996; Londono et al., 1996). Other bacterial vaccine
trains such as Streptococcus gordonii or Bacille
almette-Guerin (BCG) carrying HPV proteins were also
ested, but E7-specific CMI was not examined with the
irst strain (Medaglini et al., 1997), while E7-specific CTLs
ere reported with the second strain, but no tumor pro-
ection effect was observed (Jabbar et al., 2000). Using
CG, L1-specific CMI was also induced, but only low
nti-VLP immune responses were observed and L1-spe-
ific CTLs and tumor protection effect were not exam-
ned (Jabbar et al., 2000). The success of our approach
robably relates to the high immunogenicity of the VLPs
hat have been shown to induce both antibody re-
FIG. 4. Tumor protection after immunization with HPV16 VLPs or GL0
hown for each immunization group at day 32 after C3 cell challenge. Tu
umor volumes are shown by horizontal bars. Statistical comparisonsponses and CMI at low doses and in the absence of
djuvants (Balmelli et al., 1998; Greenstone et al., 1998; ae Bruijn et al., 1998; and this study). This suggests that
LPs, through their particulate nature, their ability to bind
o surface molecules, or their behavior similar to native
irions, are efficiently processed and presented as both
HC II and MHC I antigens (Greenstone et al., 1998; De
ruijn et al., 1998; Rudolf et al., 1999; and data not
hown). This is also true in the context of Salmonella,
here in addition the particular attenuation of the bac-
eria is important as we have shown for the induction of
PV16 VLP-specific antibody responses (Benyacoub et
l., 1999). Recombinant Salmonella engineered to ex-
ress chimeric VLP-containing E7 or other HPV early
roteins will retain the architecture of VLPs and thus the
apacity to be efficiently presented to the immune sys-
em and to induce both VLP-specific antibodies and
7-specific CTLs. Such recombinant Salmonella thus ap-
ear to be promising vaccines against HPV16 infection
nd cervical cancer. These live vaccines are easy to
roduce and administer and thus are particularly suit-
ble for use in developing countries, where cervical
ancer is the leading cause of cancer-related deaths in
omen.
MATERIALS AND METHODS
Purified VLPs and recombinant S. typhimurium strains.
aculovirus-derived HPV16 VLPs were purified as al-
eady described (Balmelli et al., 1998; Kirnbauer et al.,
992). The construction of the PhoPc S. typhimurium
strain (CS022 (Miller and Mekalanos, 1990)) expressing
HPV16 L1 has been reported previously (Nardelli-
Haefliger et al., 1997). We have used an asd (aspartate
b-semialdehyde dehydrogenase) balanced-lethal vec-
tor–host system (Curtiss et al., 1990) to generate a Dasd
derivative of PhoPc named GL01. In this system, the
6L1 in a therapeutic setting. The tumor volumes of individual mice are
e mice are indicated by the respective symbols under the x axis. Mean
eans were carried out using Student’s t test.1/HPV1Salmonella strain is deleted in the essential asd gene
nd the lack of asd is complemented by the plasmid
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and the stable expression of HPV16 L1 are reported
elsewhere (Benyacoub et al., in preparation). Briefly, the
hoPc strain was deleted in the asd gene by P22 phage
transduction (Scho¨del et al., 1994) and the resulting GL01
strain was electroporated with a plasmid encoding asd
alone (kindly provided by Dr. Roy Curtiss III, St. Louis,
MO) (GL01/pYA3342) or together with HPV16 L1 (GL01/
pYA3342-HPV16L1; referred to in this article as GL01/
HPV16L1).
Vaccination of mice. Female 6-week-old C57BL/6 mice
were used in all experiments. Subcutaneous and intra-
nasal immunization under anesthesia and oral immuni-
zation were performed as already described (Hopkins et
al., 1995; Nardelli-Haefliger et al., 1997; Balmelli et al.,
1998). The doses and schedules of VLPs or S. typhi-
murium administration were chosen according to our
previous experiments in BALB/c mice for the induction of
antigen-specific antibodies (Hopkins et al., 1995;
Nardelli-Haefliger et al., 1997; Balmelli et al., 1998), i.e.,
two 5-mg doses of purified VLPs given sc 2 weeks apart,
three 5-mg doses of purified VLPs given i.n. weekly, 107
or 109 CFU of Salmonella recombinant strains given, i.n.
or orally, respectively, 2 weeks apart. Salmonella inocula
were prepared by growing the bacteria to stationary
phase for PhoPc/HPV16L1 or to midexponential phase for
the two GL01 strains. The bacteria were then harvested
and diluted in PBS to about 107 or 109 CFU/10 ml for i.n.
and oral immunization, respectively.
Tumor challenge. The mice were sc injected in their
lank with 0.5 3 106 C3 cells, which express HPV16
genes including L1 (De Bruijn et al., 1998), 2 or 4 weeks
after the last immunization in the prophylactic setting or
6 days before the first immunization in the therapeutic
setting. The early time point of 6 days after C3 challenge
was chosen, even though a tumor was palpable in only
about 50% of the mice (.8 mm3). This is a compromise
between the fast-growing rate of the C3 cells, which
reach a tumor size corresponding to 1/10 of the mouse
body weight in 30 days, and the lag time necessary to
mount an adapted immune response. Indeed, 4 days
after the first immunization, 85% of the mice exhibited a
palpable tumor in both control and vaccinated groups.
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